| A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702) (NCT03520959) | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2018-09-18 |
| Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142) (NCT02501473) | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2016-02-03 |
| Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002) (NCT02609984) | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2015-04-29 |
| Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 (NCT02387125) | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2015-02-28 |
| Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 (NCT02122861) | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2014-05-30 |
| A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma (NCT02035657) | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2014-01-01 |
| A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer (NCT02015416) | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2013-11-01 |